The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Prevalence and Clinical Outcomes of Eosinophilic COPD in a Saudi Population: A Retrospective Study
Open accessAbstract
Objective: This study assessed the prevalence of eosinophilic chronic obstructive pulmonary disease (COPD) among a selected Saudi population and examined its correlation with baseline characteristics, clinical outcomes, exacerbation risk, and current management. Materials and Methods: This retrospective single-center study was conducted over a 2-year period. The patients were divided into two groups based on the blood eosinophil count at the time of diagnosis: eosinophilic COPD (≥300 cells/μl) and non-eosinophilic COPD (<300 cells/μl) groups. Results: Overall, 156 patients were included, of which 76 (48.7%) and 80 (51.3%) patients belonged to the eosinophilic and non-eosinophilic COPD groups, respectively. There were no significant differences between both groups regarding age, gender, smoking status, coexisting morbidities, FEV1, FEV1/FVC, and COPD severity (for all, P >0.05). Besides, there were no significant differences between both groups regarding the frequency and numbers of exacerbations, emergency room visits, in-patient hospitalizations, and intensive care unit admissions (for all, P >0.05). Among patients with eosinophilic COPD, 64 patients (84.2%) were correctly receiving the triple therapy of long-acting β2 agonists + long-acting muscarinic antagonist + inhaled corticosteroids, whereas 4 patients (5.26%) were incorrectly receiving the dual therapy of long-acting β2 agonists + inhaled corticosteroids. Univariate regression analyses revealed that heart failure, GOLD 3 severity, use of triple therapy, and use of non-invasive ventilation were significantly correlated with a higher risk of COPD exacerbation. Conversely, higher FEV1 was significantly correlated with lower risk of COPD exacerbation. The eosinophilic COPD phenotype was not found to be a significant independent variable of COPD exacerbation. Conclusion: This study found that among Saudi patients with COPD, there was no clinically important relationship between baseline blood eosinophil count and the rate of exacerbation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Eosinophilic phenotypes, obesity-associated COPD, psychological symptom burden, and viral-associated exacerbations were increasingly recognized as clinically important contributors that may be associated with disease progression and acute-care utilization [19,20,21].”
From Chronic Obstructive Pulmonary Disease in the Gulf Cooperation Council: Acute-Care Utilization and Medication Adherence: A PRISMA-ScR Scoping Review (2026) · cites this paper as [21]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Alshehri et al. [21] reported a 48.7%prevalence of eosinophilic COPD in Saudi Arabia”
From Chronic Obstructive Pulmonary Disease in the Gulf Cooperation Council: Acute-Care Utilization and Medication Adherence: A PRISMA-ScR Scoping Review (2026) · cites this paper as [21]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vos, T., Lim, S. S., Abbafati, C., Abbas, K. M., Abbasi, M., Abbasifard, M., Abbasi-Kangevari, M., Abbastabar, H., Abd-Allah, F., Abdelalim, A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30925-9 · Cited by 19,358
Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease
Hurst, J. R., Vestbo, J., Anzueto, A., Locantore, N., Müllerova, H., Tal-Singer, R., Miller, B., Lomas, D. A., Agusti, A., MacNee, W., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909883 · Cited by 2,981
Adeloye, D., Song, P., Zhu, Y., Campbell, H., Sheikh, A., & Rudan, I. (2022) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00511-7 · Cited by 1,330
Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD
Lipson, D. A., Barnhart, F., Brealey, N., Brooks, J., Criner, G. J., Day, N. C., Dransfield, M. T., Halpin, D. M. G., Han, M. K., Jones, C. E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713901 · Cited by 1,253
Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary
Agustí, A., Celli, B. R., Criner, G. J., Halpin, D., Anzueto, A., Barnes, P., Bourbeau, J., Han, M. K., Martinez, F. J., Montes de Oca, M., et al. (2023) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202301-0106pp · Cited by 827
Pascoe, S., Locantore, N., Dransfield, M. T., Barnes, N. C., & Pavord, I. D. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(15)00106-x · Cited by 743
Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD
Rabe, K. F., Martinez, F. J., Ferguson, G. T., Wang, C., Singh, D., Wedzicha, J. A., Trivedi, R., St. Rose, E., Ballal, S., McLaren, J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1916046 · Cited by 690
Global Burden of Chronic Obstructive Pulmonary Disease Through 2050
Boers, E., Barrett, M., Su, J. G., Benjafield, A. V., Sinha, S., Kaye, L., Zar, H. J., Vuong, V., Tellez, D., Gondalia, R., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.46598 · Cited by 663
Papi, A., Vestbo, J., Fabbri, L., Corradi, M., Prunier, H., Cohuet, G., Guasconi, A., Montagna, I., Vezzoli, S., Petruzzelli, S., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30206-x · Cited by 603
Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes
Reddel, H. K., Bacharier, L. B., Bateman, E. D., Brightling, C. E., Brusselle, G. G., Buhl, R., Cruz, A. A., Duijts, L., Drazen, J. M., FitzGerald, J. M., et al. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202109-2205pp · Cited by 512
Cited by
Elshafei, A., Safi, I., Aljoaid, A., Alanazi, O., & Almahd, S. (2026) · Healthcare · doi:10.3390/healthcare14131962
Alzahrani, A., Alghamdi, S. M., Majrshi, M. S., Alasmari, A., Alshehri, Z., Alahmadi, F., Qahtani, S. A., Alhawsawi, A., Alasimi, A. H., Eilayyan, O., et al. (2025) · Journal of Medical Rehabilitation Science · doi:10.4197/mrs.2-2.5
Serdyukova, T. V., Khokhlova, V. V., & Velichko, D. I. (2025) · Современные проблемы науки и образования · doi:10.17513/spno.34435
Ghobain, M. A., Alsowayan, W. A., Juma, A., Yousif, A., Almogren, R., Kahtani, R. S. A., Aldossari, M. A., & Zurnuq, H. (2026) · Annals of Thoracic Medicine · doi:10.4103/atm.atm_361_25
“[17] Severed limitations should be considered during interpretations of our findings; it is a retrospective data review in nature, evaluating serum eosinophilic count, which can be variable over time.”
The Societal and Economic Burden of COPD in Saudi Arabia
Elsisi, G. H., Alsowayan, W. A., Habis, Y., Alwakeel, A. J., Aljuwayed, H. S., Alghamdi, B. J., Al-Lehebi, R. O., Tayeb, N., Hamid, Y., Alkoraishi, A., et al. (2026) · Global Journal on Quality and Safety in Healthcare · doi:10.36401/jqsh-25-20
“[20] In alignment with the 2024 GOLD guidelines, [5] and Delphi panel recommendations, COPD treatment pathways in Saudi Arabia were defined as follows: Group A: managed with daily LAMA and as-needed short-acting beta-agonist (SABA).”
Self-citation
Metadata
- Authors
- Alshehri, F., Alghamdi, M., Aloqabi, F. A., Ibrahim, A., Tayeb, N., Hassosah, M., Abu-Zaid, A., Fan, H., & Vali, Y.
- Affiliations
- King Fahd Armed Forces Hospital (SA)
- Department of Biochemistry and Molecular Medicine, Alfaisal University, Riyadh, Saudi Arabia
- Department of Medicine, King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia
- Venue
- Saudi Journal of Medicine & Medical Sciences
- Published
- 2025-01
- Volume
- 13
- Issue
- 1
- Pages
- 53-60
- ISSN
- 1658-631X (ISSN-L)
- PMC
- PMC11809759
- OpenAlex
- W4406301140
- Semantic Scholar
- 1434a861c3dd552e644263d48a51b4be7ac16b2d
- Cited by
- 3
- References
- 37
- Citations by year
- 2026: 3
- FWCI
- 1.96
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- Locations
- Saudi Journal of Medicine and Medical Sciences (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cystic Fibrosis Research Advances
- Keywords
- eosinophilic COPD, chronic obstructive pulmonary disease, eosinophil count, COPD exacerbation risk, triple therapy, long-acting muscarinic antagonist, inhaled corticosteroids, heart failure, non-invasive ventilation, FEV1, Saudi patients
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prevalence and Clinical Outcomes of Eosinophilic COPD in a Saudi Population: A Retrospective Study. https://app.cochat.ai/papers/10.4103/sjmms.sjmms_248_24
- The paper
- Alshehri, F., Alghamdi, M., Aloqabi, F. A., Ibrahim, A., Tayeb, N., Hassosah, M., Abu-Zaid, A., Fan, H., & Vali, Y. (2025). Prevalence and Clinical Outcomes of Eosinophilic COPD in a Saudi Population: A Retrospective Study. Saudi Journal of Medicine & Medical Sciences. https://doi.org/10.4103/sjmms.sjmms_248_24
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.